natgillin/translations-raw huggingface dataset:
The mechanism by which enzalutamide may lower the seizure threshold is not known, but could be related to data from in vitro studies showing that enzalutamide and its active metabolite bind to and can inhibit the activity of the GABA-gated chloride channel. 
Mehanizem, po katerem lahko enzalutamid zniža prag za konvulzije, ni znan, lahko pa bi bil povezan s podatki iz študij in vitro, ki so pokazale, da se enzalutamid in njegov aktivni presnovek vežeta na GABA kloridne kanalčke in lahko zavreta njihovo aktivnost.
The pharmacokinetics of enzalutamide have been evaluated in prostate cancer patients and in healthy male subjects. 
Farmakokinetiko enzalutamida so ocenili pri bolnikih z rakom prostate in pri zdravih moških preiskovancih.
The transport protein P-gp may also be induced, and probably other transporters as well, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer resistance protein (BCRP) and the organic anion transporting polypeptide 1B1 (OATP1B1). 
Induciran je lahko tudi transportni protein P-gp in prav tako ostali prenašalci, npr. protein za multiplo odpornost na zdravila 2 (MRP2 - multidrug resistance-associated protein 2), protein odpornosti za raka dojke (BCRP - breast cancer resistance protein) in polipeptidni prenašalec organskih anionov 1B1 (OATP1B1 - organic anion transporting polypeptide 1B1).
Enzalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products (see examples in section 4.5). 
Enzalutamid je močan induktor encimov, kar lahko vodi do zmanjšanja učinkovitosti mnogih pogosto uporabljanih zdravil (glejte primere v poglavju 4.5).
Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression. 
Zdravljenje z enzalutamidom zmanjša rast celic raka prostate in lahko inducira odmrtje rakavih celic in regresijo tumorja.
Key secondary endpoints assessed in the study were time to PSA progression, time to first use of new antineoplastic therapy (TTA), overall survival (OS). 
Ključni sekundarni opazovani dogodki, ocenjeni v študiji, so bili čas do napredovanja PSA, čas do prve uporabe novega antineoplastičnega zdravljenja (TTA) in celokupno preživetje (OS).
If any of the above applies to you or you are not sure, talk to your doctor before taking this medicine. 
Če kaj od naštetega velja za vas, ali če niste prepričani, se pred jemanjem tega zdravila posvetujte s svojim zdravnikom.
Common: ischemic heart disease† Not known*: QT-prolongation (see sections 4.4 and 4.5) 
Srčne bolezni pogosti: ishemična srčna bolezen† neznana*: podaljšanje intervala QT (glejte poglavji 4.4 in 4.5)
BCRP, MRP2, OAT3 and OCT1 substrates 
Substrati BCRP, MRP2, OAT3 in OCT1
In preclinical studies, the absorption of enzalutamide was increased when dissolved in caprylocaproyl macrogolglycerides. 
V predkliničnih študijah je bila absorpcija enzalutamida povečana, če je le-ta bil raztopljen v kaprilat kaprinat makrogolglicerolu.
- Do not take a double dose to make up for the dose you forgot. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
- Swallow the tablets whole with water. 
Tablete pogoltnite cele in z vodo.
- Swallow the soft capsules whole with water. 
Mehke kapsule pogoltnite cele in z vodo.
(≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene takole: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Radiographic progression was assessed with the use of sequential imaging studies as defined by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria (for bone lesions) and/or Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) criteria (for soft tissue lesions). 
Radiografsko napredovanje bolezni je bilo ocenjeno s pomočjo študij sekvenčnega slikanja po kriterijih PCWG2 (Prostate Cancer Clinical Trials Working Group 2) (za kostne lezije) in/ali kriterijih RECIST različica 1.1 (Response Evaluation Criteria in Solid Tumors) (za lezije v mehkem tkivu).
You should not start or stop taking any medicine before you talk with the doctor that prescribed Xtandi. 
Nobenega zdravila ne začnite in ne nehajte jemati, dokler se ne posvetujete z zdravnikom, ki vam je predpisal zdravilo Xtandi.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
The efficacy and safety of enzalutamide in patients with metastatic CRPC who had received docetaxel and were using a LHRH analogue or had undergone orchiectomy were assessed in a randomised, placebo-controlled, multicentre phase 3 clinical trial. 
Učinkovitost in varnost enzalutamida pri bolnikih z metastatskim KORP, ki so prejemali docetaksel in so uporabljali analog LHRH ali so opravili orhidektomijo, so ocenili v randomiziranem, s placebom kontroliranem multicentričnem kliničnem preskušanju 3. faze.
PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizure, headache, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. 
PRES je redka, reverzibilna, nevrološka motnja, ki se lahko kaže s hitro razvijajočimi simptomi, vključno s konvulzijami, glavobolom, zmedenostjo, izgubo vida in drugimi vidnimi in nevrološkimi motnjami, ki so lahko ali pa niso povezani s povišanim krvnim tlakom.
Uncommon (may affect up to 1 in 100 people) Hallucinations, difficulty thinking clearly, low white blood cell count 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) halucinacije, težave z jasnim razmišljanjem, majhno število belih krvnih celic
Please tell your doctor if you have any of the following: 
Povejte svojemu zdravniku, če imate karkoli od naštetega:
Animal studies showed that enzalutamide affected the reproductive system in male rats and dogs (see section 5.3). 
Študije na živalih so pokazale, da enzalutamid vpliva na reproduktivni sistem samcev pri podganah in psih (glejte poglavje 5.3).
At study entry, 41% of randomised patients had PSA progression only, whereas 59% of patients had radiographic progression. 
Ob vstopu v študijo je imelo samo napredovanje PSA 41 % randomiziranih bolnikov, radiografsko napredovanje bolezni pa je imelo 59 % bolnikov.
18.4 (17.3, NR) 
18,4 (17,3, ND)
Enzalutamide is metabolised by CYP2C8 and to a lesser extent by CYP3A4/5 (see section 4.5), both of which play a role in the formation of the active metabolite. 
Enzalutamid se presnovi s CYP2C8 in v manjši meri s CYP3A4/5 (glejte poglavje 4.5); oba igrata vlogo pri nastanku aktivnega presnovka.
Most (91%) patients had metastases in bone and 23% had visceral lung and/or liver involvement. 
Večina (91 %) bolnikov je imela metastaze v kosteh, 23 % pa jih je imelo visceralno prizadetost pljuč in/ali jeter.
Enzalutamide has not been evaluated in patients with severe renal impairment (CrCL < 30 mL/min) or end-stage renal disease, and caution is advised when treating these patients. 
Enzalutamida niso raziskali pri bolnikih s hudo okvaro ledvic (CrCL < 30 ml/min) ali končno odpovedjo ledvic; pri zdravljenju teh bolnikov je potrebna previdnost.
Figure 8: Overall survival by subgroup in the AFFIRM study - Hazard ratio and 95% confidence interval 
Slika 8: Celokupno preživetje po podskupinah v študiji AFFIRM - razmerje ogroženosti in 95 % interval zaupanja
With daily oral administration, enzalutamide accumulates approximately 8.3-fold relative to a single dose. 
Med vsakodnevno peroralno uporabo se enzalutamid kopiči približno 8,3-kratno v primerjavi s posameznim odmerkom.
If you have any further questions on the use of this medicine, ask your doctor. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom.
Elimination The mean apparent clearance (CL/F) of enzalutamide in patients ranges from 0.520 and 0.564 L/h. 
Izločanje Povprečni navidezni očistek (CL/F) enzalutamida je pri bolnikih od 0,520 do 0,564 l/h.
The solubility of enzalutamide is increased by caprylocaproyl macrogolglycerides as emulsifier/surfactant. 
Topnost enzalutamida je povečana s pomočjo kaprilat kaprinat makrogolglicerola kot emulgatorja/površinsko aktivno snovjo.
It is not known whether enzalutamide or its metabolites are present in semen. 
Ni znano, ali se enzalutamid ali njegovi presnovki pojavijo v semenu.
If a patient misses taking Xtandi at the usual time, the prescribed dose should be taken as close as possible to the usual time. 
Če bolnik pozabi vzeti zdravilo Xtandi ob običajnem času, mora predpisani odmerek vzeti čim bližje običajnemu času.
Xtandi is used to treat adult men with prostate cancer that no longer responds to androgen deprivation therapy. 
Zdravilo Xtandi uporabljamo za zdravljenje odraslih moških z rakom prostate, ki se ne odziva več na zdravljenje z odtegnitvijo androgena.
The film-coated tablets should not be cut or crushed. 
Filmsko obloženih tablet se ne sme lomiti oziroma drobiti.
Additional secondary endpoints included time to first use of cytotoxic chemotherapy and chemotherapy-free survival. 
Med dodatnimi sekundarnimi opazovanimi dogodki sta bila čas do prve uporabe citotoksične kemoterapije in preživetja brez kemoterapije.
This medicine has moderate effect on your ability to drive or use any tools or machines as the side effects of Xtandi include psychiatric and neurological events including seizure. 
To zdravilo ima zmeren vpliv na vašo sposobnost upravljanja vozil in uporabo orodij ali strojev, ker neželeni učinki zdravila Xtandi vključujejo psihiatrične in nevrološke učinke, vključno z napadom krčev.
HR is based on a Cox regression model (with treatment as the only covariate) stratified by PSA doubling time and prior or concurrent use of a bone targeting agent. 
ROg temelji na Coxovem regresijskem modelu (z zdravljenjem kot edino sospremenljivko) s stratifikacijo po času podvojitve PSA in predhodno ali sočasno uporabo sredstev, usmerjenih na kosti.
Xtandi contains sorbitol 
Zdravilo Xtandi vsebuje sorbitol
Enzalutamide competitively inhibits androgen binding to androgen receptors, and consequently; inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens. 
Enzalutamid kompetitivno zavre vezavo androgenov na androgenske receptorje, in posledično zavre jedrno translokacijo aktiviranih receptorjev in zavre povezavo aktiviranih androgenskih receptorjev z DNA tudi v okoliščinah čezmerne ekspresije androgenskih receptorjev in v celicah raka prostate, odpornih proti androgenom.
Enzalutamide was not phototoxic in vitro. 
Enzalutamid in vitro ni bil fototoksičen.
- If you forget to take Xtandi at the usual time, take your usual dose as soon as you remember. 
Če ste pozabili vzeti zdravilo Xtandi ob običajnem času, vzemite svoj običajni odmerek, čim se spomnite.
• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1). 
• zdravljenje odraslih moških z nemetastatskim, proti kastraciji odpornim rakom prostate (KORP) z velikim tveganjem (glejte poglavje 5.1),
Patients were required to have a PSA doubling time ≤ 10 months, PSA ≥ 2 ng/mL, and confirmation of non-metastatic disease by blinded independent central review (BICR). 
Bolniki so morali imeti čas podvojitve PSA ≤ 10 mesecev, PSA ≥ 2 ng/ml in nemetastatsko bolezen, potrjeno s slepim neodvisnim centralnim pregledom (BICR - blinded independent central review).
CYP3A4 plays a minor role in the metabolism of enzalutamide. 
CYP3A4 ima pri presnovi enzalutamida le majhno vlogo.
Additional changes to reproductive tissues included hypertrophy/hyperplasia of the pituitary gland and atrophy in seminal vesicles in rats and testicular hypospermia and seminiferous tubule degeneration in dogs. 
Med drugimi spremembami reproduktivnih tkiv so bile hipertrofija/hiperplazija hipofize in atrofija seminalnih vezikul pri podganah ter testikularna hipospermija in degeneracija semenskih tubulov pri psih.
The median age was 71 years (range 42 - 93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% other or unknown races. 
Mediana starost je bila 71 let (razpon od 42 do 93) in porazdelitev glede na raso je bila 77 % belcev, 10 % azijcev, 2 % črncev in 11 % druge ali neznane rase.
Daily dosing of rats for two years with enzalutamide at 10-100 mg/kg/day produced an increased incidence of several, mostly benign, tumour types. 
Vsakodnevna 2-letna uporaba od 10 do 100 mg enzalutamida/kg/dan je pri podganah povečala pojavnost več vrst (večinoma benignih) tumorjev.
Do not take any soft capsule that is leaking, damaged, or shows signs of tampering. 
Ne jemljite mehkih kapsul, ki puščajo, so poškodovane ali če opazite znake odpiranja.
Oral absorption of film-coated enzalutamide tablets was evaluated in healthy male volunteers after a single 160 mg dose of Xtandi film-coated tablets, and pharmacokinetic modelling and simulation were used to predict the pharmacokinetic profile at steady state. 
Peroralno absorpcijo filmsko obloženih tablet enzalutamida so ocenili pri zdravih moških prostovoljcih po enkratnem 160-mg odmerku zdravila Xtandi v filmsko obloženih tabletah in za napoved farmakokinetičnega profila v stanju dinamičnega ravnovesja sta bila uporabljena farmakokinetično modeliranje in simulacija.
The risk for liver injury after paracetamol administration is suspected to be higher in patients concomitantly treated with enzyme inducers. 
Tveganje za poškodbe jeter po jemanju paracetamola je lahko večje pri bolnikih, ki se sočasno zdravijo z induktorji encimov.
Other medicines and Xtandi 
Druga zdravila in zdravilo Xtandi
Elderly No dose adjustment is necessary for elderly patients (see sections 5.1 and 5.2). 
Starejši bolniki Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavji 5.1 in 5.2).
The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. 
Sočasni uporabi močnih zaviralcev CYP2C8 se je treba izogniti, če je mogoče.
There is no relevant use of enzalutamide in the paediatric population in the indication of treatment of adult men with CRPC. 
Enzalutamid ni primeren za uporabo pri pediatrični populaciji za indikacijo zdravljenje odraslih moških s KORP.
The study design could neither identify the patients who are likely to benefit, nor the order in which enzalutamide and abiraterone should be optimally sequenced. 
Glede na načrt raziskave ni možno prepoznati bolnikov, ki bi imeli največje koristi od zdravljenja, niti ni možno prepoznati v kašnem zaporedju naj se uporabljata enzalutamid in abirateron, da bi bilo to najbolj optimalno.
The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days), and steady state is achieved in approximately one month. 
Povprečni terminalni razpolovni čas (t1/2) enzalutamida je pri bolnikih po posameznem peroralnem odmerku 5,8 dneva (razpon: od 2,8 do 10,2 dneva), stanje dinamičnega ravnovesja pa je doseženo v približno enem mesecu.
- If you have any further questions, ask your doctor. 
Če imate dodatna vprašanja, se posvetujte z zdravnikom.
Concomitant use of enzalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters (see section 4.5) should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations. 
Sočasni uporabi enzalutamida z zdravili, ki so občutljivi substrati mnogih presnovnih encimov ali prenašalcev (glejte poglavje 4.5) se je v večini potrebno izogniti, če imajo ta zdravila velik terapevtski učinek na bolnika in prilagoditev odmerka ni mogoče enostavno izvesti na osnovi spremljanja učinkovitosti ali koncentracij v plazmi.
If their therapeutic effect is of large importance to the patient, and dose adjustments are not easily performed based on monitoring of efficacy or plasma concentrations, these medicinal products are to be avoided or used with caution. 
Če je njihov terapevtski učinek na bolnika velik in prilagajanje njihovega odmerka na osnovi spremljanja učinkovitosti ali koncentracij v plazmi ni enostavno, se je sočasni uporabi teh zdravil potrebno izogniti ali pa jih uporabljati previdno.
If you forget to take Xtandi 
Če ste pozabili vzeti zdravilo Xtandi
In addition to the co-primary endpoints, benefit was also assessed using time to initiation of cytotoxic chemotherapy, best overall soft tissue response, time to first skeletal-related event, PSA response (≥ 50% decrease from baseline), time to PSA progression, and time to FACT-P total score degradation. 
Poleg sočasnih primarnih opazovanih dogodkov so korist ocenili tudi s pomočjo časa do uvedbe citotoksične kemoterapije, najboljšega celokupnega odziva mehkega tkiva, časa do pojava prvega z okostjem povezanega dogodka, odziva PSA (zmanjšanje za ≥ 50 % od izhodišča), časa do napredovanja PSA in časa do upada skupne ocene FACT-P.
White to off-white oblong soft capsules (approximately 20 mm x 9 mm) imprinted with “ENZ” in black ink on one side. 
Bele do skoraj bele, podolgovate mehke kapsule (velike približno 20 mm x 9 mm), ki imajo na eni strani s črnim črnilom natisnjeno oznako "ENZ".
A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). 
Diagnozo potrdimo s slikanjem možganov, najbolje z magnetno resonanco (MR).
35.3 (32.2, NR) 31.3 (28.8, 34.2) 
35,3 (32,2, ND) 31,3 (28,8, 34,2)
What Xtandi is and what it is used for What you need to know before you take Xtandi How to take Xtandi 
Kaj je zdravilo Xtandi in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Xtandi Kako jemati zdravilo Xtandi Možni neželeni učinki
• the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1). 
• zdravljenje odraslih moških z metastatskim KORP, ki so asimptomatski ali blago simptomatski po nedelovanju zdravljenja z odtegnitvijo androgena, pri katerih kemoterapija še ni klinično indicirana (glejte poglavje 5.1),
Risk of seizure 
Tveganje za konvulzije
The soft capsules should not be dissolved or opened. 
Mehkih kapsul se ne sme raztopiti ali odpirati.
The volume of distribution of enzalutamide is greater than the volume of total body water, indicative of extensive extravascular distribution. 
Volumen porazdelitve enzalutamida je večji od volumna celotne telesne vode.
Based on these predictions, as well as other supportive data, the median time to reach maximum plasma enzalutamide concentrations (Cmax) is 2 hours (range 0.5 to 6 hours), and the steady-state pharmacokinetic profiles of enzalutamide and its active metabolite are similar for the film-coated tablets and the Xtandi soft capsules formulation. 
Na podlagi teh napovedi in drugih podpornih podatkov je mediani čas do dosežene največje koncentracije (Cmax) enzalutamida v plazmi 2 uri (razpon: od 0,5 do 6 ur) in farmakokinetični profil enzalutamida in njegovih aktivnih presnovkov je v stanju dinamičnega ravnovesja med uporabo filmsko obloženih tablet podoben kot med uporabo mehkih kapsul zdravila Xtandi.
Hepatic impairment did not have a pronounced effect on the total exposure to enzalutamide or its active metabolite. 
Okvara jeter ni imela izrazitega vpliva na celokupno izpostavljenost enzalutamidu ali njegovim aktivnim presnovkom.
Enzymes that may be induced include CYP3A in the liver and gut, CYP2B6, CYP2C9, CYP2C19, and uridine 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enzymes). 
Možni inducirani encimi lahko vključujejo CYP3A v jetrih in črevesju, CYP2B6, CYP2C9, CYP2C19 in uridin 5'-difosfat-glukuronil-transferazo (UGT - glukuronidni konjugacijski encimi).
In vitro, N-desmethyl enzalutamide is metabolised to the carboxylic acid metabolite by carboxylesterase 1, which also plays a minor role in the metabolism of enzalutamide to the carboxylic acid metabolite. 
N-desmetil enzalutamid se in vitro presnovi v presnovek karboksilne kisline s karboksilesterazo 1, ki ima tudi manjšo vlogo pri presnovi enzalutamida v presnovek karboksilne kisline.
Of the 3179 patients in the controlled clinical trials who received enzalutamide, 2518 patients (79%) were 65 years and over and 1162 patients (37%) were 75 years and over. 
Od 3179 bolnikov v kontroliranih kliničnih preskušanjih, ki so prejemali enzalutamid, jih je bilo 2518 (79 %) starih 65 let ali več in 1162 (37 %) starih 75 let ali več.
Enzalutamide treatment of pregnant mice resulted in an increased incidence of embryo-fetal deaths and external and skeletal changes. 
Dajanje enzalutamida brejim mišim je povzročilo večjo incidenco embrio-fetalnih smrti in zunanjih sprememb ter sprememb okostja.
In clinical trials, Xtandi was administered without regard to food. 
V kliničnih preskušanjih so zdravilo Xtandi uporabljali ne glede na hrano.
If you have a seizure, see your doctor as soon as possible. 
Če se vam pojavi napad krčev, čim prej obiščite svojega zdravnika.
No major deviations from dose proportionality are observed over the dose range 40 to 160 mg. 
V razponu odmerkov od 40 do 160 mg niso opazili večjih odklonov od sorazmernosti odmerku.
Co-administration of enzalutamide has no clinically relevant effect on the pharmacokinetics of intravenous docetaxel (see section 4.5); however, an increase in the occurrence of docetaxel-induced neutropenia cannot be excluded. 
Sočasno dajanje enzalutamida nima klinično pomembnega učinka na farmakokinetiko intravensko uporabljenega docetaksela (glejte poglavje 4.5), vendar pa povečanja pojavnosti nevtropenije zaradi docetaksela ni mogoče izključiti.
The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L (29% CV). 
Povprečni navidezni volumen porazdelitve (V/F) enzalutamida je pri bolnikih po posameznem peroralnem odmerku 110 l (KV 29 %).
The dose of Xtandi or any other medicines that you are taking may need to be changed. 
Morda vam bo moral spremeniti odmerek zdravila Xtandi ali kakšnih drugih zdravil, ki jih jemljete.
• Antipsychotics (e.g. haloperidol) 
• antipsihotiki (npr. haloperidol)
You may have an increased risk of seizure or other side effects. 
Poveča se vam lahko tveganje za napade krčev (konvulzije) ali druge neželene učinke.
Enzalutamide and/or its metabolites are secreted in rat milk (see section 5.3). 
Enzalutamid in/ali njegovi presnovki se pri podganah izločajo v mleko (glejte poglavje 5.3).
In vitro data indicate that enzalutamide and its major metabolites do not inhibit the following transporters at clinically relevant concentrations: OATP1B1, OATP1B3, OCT2, or OAT1. 
Podatki in vitro kažejo, da enzalutamid in njegovi glavni presnovki v klinično pomembnih koncentracijah ne zavirajo naslednjih prenašalcev: OATP1B1, OATP1B3, OCT2 ali OAT1.
The HR is relative to placebo with < 1 favouring enzalutamide. 
ROg je glede na placebo; vrednost < 1 je v korist enzalutamida.
Potential for enzalutamide to affect exposures to other medicinal products 
Možnost vpliva enzalutamida na izpostavljenost drugim zdravilom
Enzalutamide (N = 800) 
Enzalutamid (N = 800)
Gender differences were noted in rat mammary glands (male atrophy and female lobular hyperplasia). 
Razlike med spoloma so opazili v mlečnih žlezah podgan (atrofija pri samcih in lobularna hiperplazija pri samicah).
32.4 (30.1, NR) 30.2 (28.0, NR) 
32,4 (30,1, ND) 30,2 (28,0, ND)
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se z njim posvetujte, preden vzamete to zdravilo.